Cargando…

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model

BACKGROUND: CD101 is a novel, long acting echinocandin. The purpose of the study was to evaluate the PK/PD activity of CD101 against C. albicans (CA) and C. glabrata (CG) using the murine neutropenic disseminated candidiasis model. METHODS: 4 CA and 3 CG strains were used. MICs were determined by CL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lepak, Alexander J, Zhao, Miao, Vanscoy, Brian, Ambrose, Paul G, Andes, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631110/ http://dx.doi.org/10.1093/ofid/ofx163.1224

Ejemplares similares

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
por: Lepak, Alexander J, et al.
Publicado: (2018)

1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
por: Zhao, Miao, et al.
Publicado: (2018)

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
por: Coste, A. T., et al.
Publicado: (2020)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins
por: Hernando-Ortiz, Ainara, et al.
Publicado: (2021)

Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis
por: Rossoni, Rodnei Dennis, et al.
Publicado: (2015)

Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
por: Hager, Christopher, et al.
Publicado: (2017)

Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance
por: Grosset, Marine, et al.
Publicado: (2016)

Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
por: Healey, Kelley R., et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model
por: Zhao, Yongda, et al.
Publicado: (2018)

2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
por: Lepak, Alexander, et al.
Publicado: (2023)

Candida glabrata Binding to Candida albicans Hyphae Enables Its Development in Oropharyngeal Candidiasis
por: Tati, Swetha, et al.
Publicado: (2016)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
por: Singh-Babak, Sheena D., et al.
Publicado: (2012)

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017)

Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis
por: Gonzalez, Javier M., et al.
Publicado: (2015)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Profiles of Tulathromycin in an Experimental Intraperitoneal Haemophilus parasuis Infection Model in Neutropenic Guinea Pigs
por: Guo, Li-li, et al.
Publicado: (2021)

Clinical and Laboratory Development of Echinocandin Resistance in Candida glabrata: Molecular Characterization
por: Rivero-Menendez, Olga, et al.
Publicado: (2019)

P017 Echinocandin resistance mechanism in Candida tropicalis and Candida glabrata
por: Sharma, Dipti, et al.
Publicado: (2022)

Clinical characteristics of the first cases of invasive candidiasis in China due to pan-echinocandin-resistant Candida tropicalis and Candida glabrata isolates with delineation of their resistance mechanisms
por: Xiao, Meng, et al.
Publicado: (2018)

The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination
por: Healey, Kelley R., et al.
Publicado: (2017)

CD101: a novel long‐acting echinocandin
por: Zhao, Yanan, et al.
Publicado: (2016)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms
por: Chandra, Jyotsna, et al.
Publicado: (2018)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Two echinocandin-resistant Candida glabrata FKS mutants from South Africa
por: Naicker, Serisha D., et al.
Publicado: (2016)

Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance
por: Agnelli, Caroline, et al.
Publicado: (2019)

381. Morphologic Changes Associated With Echinocandin Tolerance Enhance Immunoevasion of Candida glabrata
por: Hu, Chenlin, et al.
Publicado: (2018)

Two Sequential Clinical Isolates of Candida glabrata with Multidrug-Resistance to Posaconazole and Echinocandins
por: Wang, Qiqi, et al.
Publicado: (2021)

Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata
por: Hu, Chenlin, et al.
Publicado: (2022)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis
por: Boikov, Dina A., et al.
Publicado: (2017)

Factor associated with oral candidiasis caused by co-infection of Candida albicans and Candida glabrata: A retrospective study
por: Hato, Hiroyuki, et al.
Publicado: (2022)

Two unlike cousins: Candida albicans and C. glabrata infection strategies
por: Brunke, Sascha, et al.
Publicado: (2013)

Divergent Approaches to Virulence in C. albicans and C. glabrata: Two Sides of the Same Coin
por: Galocha, Mónica, et al.
Publicado: (2019)

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
por: James, Kenneth D., et al.
Publicado: (2017)

1726. Candida albicans Virulence Genes Induced During Intra-abdominal Candidiasis (IAC) in the Absence of Antifungal Exposure Mediate Echinocandin Resistance
por: Clancy, Cornelius J, et al.
Publicado: (2019)

Echinocandins - first line in invasive candidiasis: how strong is this 'strong' evidence?
por: Gonçalves-Pereira, João, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_795sepbncdnsvjb8f766k4j3f0